Novo Nordisk's sales growth went from 14 percent to zero – more uncertainty ahead
Following two quarters of very different sales growth, Novo Nordisk Chief Financial Officer Karsten Munk Knudsen warns of ongoing volatility due to the Covid-19 pandemic. More side effects are expected, but the worst may well be over, according to analyst.
BY KEVIN GRØNNEMANN, TRANSLATED BY NIELSINE NIELSEN
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.